Your browser doesn't support javascript.
loading
Management of metastatic cutaneous melanoma: updates in clinical practice.
Schvartsman, Gustavo; Taranto, Patricia; Glitza, Isabella C; Agarwala, Sanjiv S; Atkins, Michael B; Buzaid, Antonio C.
Afiliación
  • Schvartsman G; Centro de Oncologia e Hematologia - Hospital Israelita Albert Einstein, 627 Albert Einstein Avenue, São Paulo, SP 05653-120, Brazil.
  • Taranto P; Department of Medical Oncology, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.
  • Glitza IC; Department of Melanoma Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
  • Agarwala SS; Department of Hematology and Oncology, and Temple University, Easton, PA, USA.
  • Atkins MB; Department of Oncology, Georgetown University School of Medicine, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC, USA.
  • Buzaid AC; Department of Medical Oncology, Hospital Israelita Albert Einstein, São Paulo, SP, Brazila and Department of Medical Oncology, A Beneficência Portuguesa de São Paulo - BP, São Paulo, SP, Brazil.
Ther Adv Med Oncol ; 11: 1758835919851663, 2019.
Article en En | MEDLINE | ID: mdl-31205512
In recent years, several drugs have been approved for the treatment of patients with metastatic cutaneous melanoma, completely reshaping the landscape of this aggressive disease. Immune therapy with cytotoxic T-lymphocyte antigen 4 and programmed cell death-1 inhibitors yielded significant and durable responses, achieving long-term disease control in up to 40% of the patients. BRAF inhibitors (BRAFi), in combination with MEK inhibitors, also resulted in improved overall survival compared with single-agent BRAFi in patients with BRAFV600-mutated metastatic melanoma. The optimized sequencing and duration of treatment, however, is yet to be found. In this article, we thoroughly review current data and discuss how to best sequence the various treatment modalities available at present, based on four distinct clinical presentations commonly seen in clinic. In addition, we review treatment options beyond checkpoint inhibitors and targeted therapy, which may be required by patients failing such effective treatments.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Ther Adv Med Oncol Año: 2019 Tipo del documento: Article País de afiliación: Brasil Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Ther Adv Med Oncol Año: 2019 Tipo del documento: Article País de afiliación: Brasil Pais de publicación: Reino Unido